Doctors in Southampton are the first in the world to fit critically ill patients with a revolutionary bug-like device to detect dangerous blood sugar levels.
The hi-tech gadget, which consists of two probes with four sensors that are hooked into the skin and covered with a dressing, enables doctors to offer patients round-the-clock protection against life-threatening infections or seizures for the duration of their time in intensive care.
Many seriously ill patients, including those with diabetes, suffer high levels of glucose in the blood as a result of the body’s reaction to trauma or surgery and, as this increases the risk of infection, levels are usually lowered with infusions of insulin.
However, as this treatment can force glucose levels to drop too low and cause seizures or coma, patients require regular glucose monitoring.
In the past, this was managed using traditional blood test analysis, which would only take place every two to four hours – leaving patients vulnerable if sugar levels increased or dropped without warning.
An alert warning system is triggered to allow clinicians to intervene early if a patient begins to head outside of their target glucose range and prevent possible complications while, if their blood sugar alters without warning, a separate alarm is activated to prompt urgent action.
“This device is a cutting-edge advance for critically ill patients as, for the first time, we are able to constantly monitor the blood glucose levels in critically ill patients,” said Dr Paul Diprose, a consultant cardiac anaesthetist at Southampton General Hospital.
“Until this development, we were reliant on information taken and assessed every two to four hours. Many of our patients have rapidly changing blood glucose levels and this device can allow much more frequent feedback of levels and allow us to intervene early to attempt to avoid complications.”
Dr Diprose, who led a study of 25 patients fitted with the device following cardiac surgery at Southampton General, said it provided glucose levels which “correlated well” with the current time-consuming methods of glucose monitoring.
Dr Mike Herbertson, director of cardiac intensive care at University Hospital Southampton NHS Foundation Trust, added: “This device provides a continuous measure rather than intermittent ‘snapshots’ of glucose levels that we have traditionally used.
“It provides the opportunity to control patients’ blood sugar levels much more effectively than was safe to do in the past and that is an important development.”
The study was presented at a meeting of the Association of Cardiothoracic Anaesthetists in Cambridge.
The Sentrino Continuous Glucose Management System is manufactured by Medtronic. For more information, visit http://www.hospitalcriticalcare.com
University Hospital Southampton NHS Foundation Trust